Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.67+0.15 (+9.87%)
Close on Nov 18, 2026Market cap $102.90MP/E –Yield –
Voyager Therapeutics cash
Cash and short-term investments held at the end of each period.
Voyager Therapeutics's cash was $148.80M at Jun 30, 2026. For fiscal 2025 it was $201.70M, down 39.3% from the year before. Over ten years it grew 0.4% a year on average. The highest annual figure on record is $332.40M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.70M | -39.3% |
| FY2024 | Dec 31, 2024 | $332.40M | +44.0% |
| FY2023 | Dec 31, 2023 | $230.90M | +94.4% |
| FY2022 | Dec 31, 2022 | $118.80M | -11.6% |
| FY2021 | Dec 31, 2021 | $134.32M | -26.6% |
| FY2020 | Dec 31, 2020 | $182.92M | -35.2% |
| FY2019 | Dec 31, 2019 | $282.27M | +80.3% |
| FY2018 | Dec 31, 2018 | $156.54M | -7.8% |
| FY2017 | Dec 31, 2017 | $169.79M | -3.1% |
| FY2016 | Dec 31, 2016 | $175.15M | -10.0% |
| FY2015 | Dec 31, 2015 | $194.65M | +2666.9% |
| FY2014 | Dec 31, 2014 | $7.04M | +5111.1% |
| FY2013 | Dec 31, 2013 | $135.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $148.80M | -43.2% |
| Q1 FY2026 | Mar 31, 2026 | $171.70M | -41.8% |
| Q4 FY2025 | Dec 31, 2025 | $201.70M | -39.3% |
| Q3 FY2025 | Sep 30, 2025 | $229.00M | -33.7% |
| Q2 FY2025 | Jun 30, 2025 | $262.00M | -29.4% |
| Q1 FY2025 | Mar 31, 2025 | $295.10M | -26.3% |
| Q4 FY2024 | Dec 31, 2024 | $332.40M | +44.0% |
| Q3 FY2024 | Sep 30, 2024 | $345.40M | +36.6% |
| Q2 FY2024 | Jun 30, 2024 | $371.00M | +36.0% |
| Q1 FY2024 | Mar 31, 2024 | $400.50M | +46.5% |
| Q4 FY2023 | Dec 31, 2023 | $230.90M | +94.4% |
| Q3 FY2023 | Sep 30, 2023 | $252.90M | +92.2% |
| Q2 FY2023 | Jun 30, 2023 | $272.70M | +84.1% |
| Q1 FY2023 | Mar 31, 2023 | $273.30M | +63.8% |
| Q4 FY2022 | Dec 31, 2022 | $118.80M | -11.6% |
| Q3 FY2022 | Sep 30, 2022 | $131.60M | +8.3% |
| Q2 FY2022 | Jun 30, 2022 | $148.10M | +3.6% |
| Q1 FY2022 | Mar 31, 2022 | $166.80M | +8.9% |
| Q4 FY2021 | Dec 31, 2021 | $134.32M | -26.6% |
| Q3 FY2021 | Sep 30, 2021 | $121.50M | -39.2% |
| Q2 FY2021 | Jun 30, 2021 | $143.00M | -37.7% |
| Q1 FY2021 | Mar 31, 2021 | $153.10M | -39.0% |
| Q4 FY2020 | Dec 31, 2020 | $182.92M | -35.2% |
| Q3 FY2020 | Sep 30, 2020 | $200.00M | -34.9% |
| Q2 FY2020 | Jun 30, 2020 | $229.70M | -29.9% |
| Q1 FY2020 | Mar 31, 2020 | $250.90M | -30.0% |
| Q4 FY2019 | Dec 31, 2019 | $282.27M | +80.3% |
| Q3 FY2019 | Sep 30, 2019 | $307.40M | +71.2% |
| Q2 FY2019 | Jun 30, 2019 | $327.50M | +66.2% |
| Q1 FY2019 | Mar 31, 2019 | $358.50M | +64.3% |
| Q4 FY2018 | Dec 31, 2018 | $156.54M | -7.8% |
| Q3 FY2018 | Sep 30, 2018 | $179.60M | +43.0% |
| Q2 FY2018 | Jun 30, 2018 | $197.00M | +39.4% |
| Q1 FY2018 | Mar 31, 2018 | $218.20M | +38.4% |
| Q4 FY2017 | Dec 31, 2017 | $169.79M | -3.1% |
| Q3 FY2017 | Sep 30, 2017 | $125.60M | -34.3% |
| Q2 FY2017 | Jun 30, 2017 | $141.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $157.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $175.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $191.20M | – |
See a number that looks wrong?